Trial Profile

Renoprotective effects of azelnidipine in hypertensive diabetic patients in Mie

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Nov 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azelnidipine (Primary) ; Trichlormethiazide (Primary) ; Amlodipine; Olmesartan medoxomil
Indications Essential hypertension
Focus Pharmacodynamics
Acronyms RANDAM

Most Recent Events

04 Oct 2012 Primary endpoint 'Urinary-albumin:creatinine-ratio' has been met.
04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
06 Apr 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com